Your browser doesn't support javascript.
loading
Breaking Ground in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Novel Therapies Beyond PD-L1 Immunotherapy.
Rosenberg, Ari J; Perez, Cesar A; Guo, Wenji; de Oliveira Novaes, Jose Monteiro; da Silva Reis, Kamilla F Oliveira; McGarrah, Patrick W; Price, Katharine A R.
Afiliación
  • Rosenberg AJ; Department of Medicine, Section of Hematology and Oncology, University of Chicago, Chicago, IL.
  • Perez CA; Sarah Cannon Research Institute at Florida Cancer Specialists, Orlando, FL.
  • Guo W; Department of Medicine, Section of Hematology and Oncology, University of Chicago, Chicago, IL.
  • de Oliveira Novaes JM; University of Miami Sylvester Comprehensive Cancer Center/Jackson Memorial Hospital, Miami, FL.
  • da Silva Reis KFO; Fellow in Clinical Oncology, by the Foundation Center for Oncology Control (FCECON), Manaus-Amazonas, Brazil.
  • McGarrah PW; Division of Medical Oncology, Mayo Clinic, Rochester, MN.
  • Price KAR; Division of Medical Oncology, Mayo Clinic, Rochester, MN.
Am Soc Clin Oncol Educ Book ; 44(3): e433330, 2024 Jun.
Article en En | MEDLINE | ID: mdl-38718318
ABSTRACT
The treatment for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) with immune checkpoint inhibitors (anti-PD1) with or without chemotherapy has led to an improvement in survival. Yet, despite this therapeutic advancement, only 15%-19% of patients remain alive at four years, highlighting the poor survival and unmet need for improved therapies for this patient population. Some of the key evolving novel therapeutics beyond anti-PD1 in R/M HNSCC have included therapeutic vaccine therapies, bispecific antibodies/fusion proteins and multitargeted kinase inhibitors, and antibody-drug conjugates (ADCs). Multiple concurrent investigations of novel therapeutics for patients with R/M HNSCC beyond anti-PD(L)1 inhibition are currently underway with some promising early results. Beyond immune checkpoint inhibition, novel immunotherapeutic strategies including therapeutic vaccines ranging from targeting human papillomavirus-specific epitopes to personalized neoantigen vaccines are ongoing with some early efficacy signals and large, randomized trials. Other novel weapons including bispecific antibodies, fusion proteins, and multitargeted kinase inhibitors leverage multiple concurrent targets and modulation of the tumor microenvironment to harness antitumor immunity and inhibition of protumorigenic signaling pathways with emerging promising results. Finally, as with other solid tumors, ADCs remain a promising therapeutic intervention either alone or in combination with immunotherapy for patients with R/M HNSCC. With early enthusiasm across novel therapies in R/M HNSCC, results of larger randomized trials in R/M HNSCC are eagerly awaited.
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Carcinoma de Células Escamosas de Cabeza y Cuello / Inmunoterapia Límite: Humans Idioma: En Revista: Am Soc Clin Oncol Educ Book Año: 2024 Tipo del documento: Article País de afiliación: Israel Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Carcinoma de Células Escamosas de Cabeza y Cuello / Inmunoterapia Límite: Humans Idioma: En Revista: Am Soc Clin Oncol Educ Book Año: 2024 Tipo del documento: Article País de afiliación: Israel Pais de publicación: Estados Unidos